<DOC>
	<DOC>NCT00620854</DOC>
	<brief_summary>This study compares the performance of different doses of oral recombinant salmon calcitonin (rsCT).</brief_summary>
	<brief_title>A Dose Selection Study of Oral Recombinant Salmon Calcitonin (rsCT) in Normal, Healthy, Postmenopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Salmon calcitonin</mesh_term>
	<mesh_term>Calcitonin</mesh_term>
	<mesh_term>Calcitonin Gene-Related Peptide</mesh_term>
	<criteria>Postmenopausal female, in good health (at least 5 years since last menses) Age ≥45 and ≤70 Weight + or 20% of the Metropolitan Life weight table Plasma Cterminal telopeptide of type I collagen (CTx1) ≥ 0.25 ng/mL Total calcium (Ca++), phosphorus (P), and magnesium (Mg++) within normal range Willing and able to comply with all study requirements Willing and able to sign written informed consent Negative urine pregnancy test at screening Negative Screen for Hepatitis B and C, human immunodeficiency virus (HIV) and drugs of abuse History of parathyroid, thyroid, pituitary or adrenal diseases History of musculoskeletal disease History of gastroesophageal reflux disease (GERD) or other significant gastrointestinal disorders History of cancer within 5 years of enrollment other than basal cell carcinoma History of regular use of nonsteroidal antiinflammatory drugs (NSAID) History of surgery within 60 days of enrollment History of hypersensitivity or allergies (other than seasonal allergies) within 5 years of enrollment including known sensitivity to the active ingredients or the excipients in the study medications Use of concomitant medications other than acetaminophen within 7 days of enrollment or anticipated need to use such concomitant medications during the study Use of bisphosphonates within 6 months, selective selective estrogen receptor modulators (SERMS), estrogen or estrogenlike drugs 2 months, or calcitonin 1 month Presence of any clinically significant illness Unwilling or unable to comply with all study requirements Unwilling or unable to sign written, informed consent History of drug or alcohol abuse Participation in any clinical study of an investigational drug within 60 days of enrollment Plasma CTx1 less than 0.25 ng/mL</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>